Issues related to Part D Medicare and issues related to the drug industry.
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Issues relating to trade negotiations; PNTR with Russia.
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit; Issues related to corporate tax reform.
Duration: January 1, 2008
to
June 30, 2013
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $770,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2013
CAUTHEN FORBES & WILLIAMS terminated an engagement in which they represented Merck on July 22, 2013.
Original Filing: 300586484.xml
1st Quarter, 2013
In Q1, CAUTHEN FORBES & WILLIAMS did no lobbying for Merck . The report was filed on April 23, 2013.
Original Filing: 300565305.xml
4th Quarter, 2012
In Q4, CAUTHEN FORBES & WILLIAMS did no lobbying for Merck . The report was filed on Jan. 22, 2013.
Original Filing: 300542880.xml
3rd Quarter, 2012
In Q3, CAUTHEN FORBES & WILLIAMS did no lobbying for Merck . The report was filed on Oct. 22, 2012.
Original Filing: 300521518.xml
2nd Quarter, 2012
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on July 20, 2012.
Original Filing: 300497956.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations; PNTR with Russia.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit; Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on April 17, 2012.
Original Filing: 300462489.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness; issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit; issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on Jan. 20, 2012.
Original Filing: 300450082.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness; issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit; issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
In Q3, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on Oct. 18, 2011.
Original Filing: 300418367.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Iissues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit; issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on July 19, 2011.
Original Filing: 300398282.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Iissues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2011
In Q1, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on April 19, 2011.
Original Filing: 300372412.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Iissues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2010
In Q4, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $40,000. The report was filed on Jan. 19, 2011.
Original Filing: 300346634.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 3200 America's Affordable Health Choices Act of 2009, HR 3590 Patient Protection and Affordable Care Act - issues related to Part D Medicare and issues related to the drug industry, issues related to comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on Oct. 20, 2010.
Original Filing: 300326700.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. Issues related to vaccines. Issues related to PCORI.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; Issues related to comparative effectiveness; H.R. 3200 and America's Healthy Future Act of 2009; H.R. 3590.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral; issues related to the research and development tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300296576.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. Issues related to vaccines. Issues related to PCORI.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; Issues related to comparative effectiveness; H.R. 3200 and America's Healthy Future Act of 2009; H.R. 3590.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral; issues related to the research and development tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on April 19, 2010.
Original Filing: 300265062.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. Issues related to vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; Issues related to comparative effectiveness; H.R. 3200 and America's Healthy Future Act of 2009; H.R. 3590.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral; issues related to the research and development tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on Jan. 19, 2010.
Original Filing: 300237012.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. Issues related to vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; Issues related to comparative effectiveness; H.R. 3200 and America's Healthy Future Act of 2009; H.R. 3590.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216287.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Health Issues
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, HR 3200 and America's Healthy Future Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on July 16, 2009.
Original Filing: 300179348.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499 Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry, stimulus provisions, and economic recovery.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, health care reform, HR 1.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2009
In Q1, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on April 17, 2009.
Original Filing: 300155229.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499 Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry, stimulus provisions, and economic recovery.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry; issues related to comparative effectiveness, HR 1.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2008
In Q4, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on Jan. 16, 2009.
Original Filing: 300124969.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499 Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry, stimulus provisions, and economic recovery.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2008
In Q3, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on Oct. 17, 2008.
Original Filing: 300097729.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499 Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2008
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on July 21, 2008.
Original Filing: 300077409.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499, Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2008
In Q2, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on July 18, 2008.
Original Filing: 300074049.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, Children's Health and Medicare Protection Act of 2007, S 2499, Medicare, Medicaid and SCHIP Extension Act of 2007, provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2008
In Q1, CAUTHEN FORBES & WILLIAMS lobbied for Merck , earning $30,000. The report was filed on April 16, 2008.
Original Filing: 300038469.xml
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry. HR 3162, S 2499 provisions related to prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Part D Medicare and issues related to the drug industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid
Lobbying Issues
Issues relating to trade negotiations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate